Pharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancer
- Authors:
- Mina Iwai
- Michio Kimura
- Eiseki Usami
- Tomoaki Yoshimura
- Hitomi Teramachi
View Affiliations
Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan, Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu 501‑1196, Japan
- Published online on: April 10, 2017 https://doi.org/10.3892/mco.2017.1218
-
Pages:
794-798
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Comparison of the costs of capecitabine plus oxaliplatin (CapeOX) with that of FOLFOX6 (5-fluorouracil/leucovorin [LV] + oxaliplatin) as an adjuvant chemotherapy for stage II or III colorectal cancer has previously been reported. However, there are no reports comparing uracil and tegafur (UFT)/LV with capecitabine. Therefore, the current study compared the costs of adjuvant chemotherapy regimens including CapeOX, FOLFOX6, capecitabine and UFT/LV. The costs of chemotherapeutic drugs and for the prevention and treatment of adverse events were evaluated, as these account for the bulk of the treatment costs. Costs were expressed in Japanese Yen (US dollars). The mean costs of the chemotherapeutic drugs per patient, for an entire course of treatment, were ¥882,632 ($8,406) for UFT/LV, ¥353,290 ($3,365) for capecitabine, ¥1,436,218 ($13,678) for FOLFOX6 and ¥1,255,630 ($11,958) for CapeOX. The mean costs associated with adverse events per patient were ¥2,210 ($21) for UFT/LV, ¥6,749 ($64) for capecitabine, ¥173,432 ($1,652) for FOLFOX6 and ¥107,430 ($1,023) for CapeOX. Therefore, the capecitabine regimen contributes to reducing costs for the management of patients with colorectal cancer who have had surgery.
View References
|
1
|
Foundation for promotion cancer research:
Cancer statistics in Japan. http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2014_jp.htmlAccessed.
May 14–2016.
|
|
2
|
Efficacy of adjuvant fluorouracil and
folinic acid in B2 colon cancer. International multicentre pooled
analysis of B2 colon cancer trials (IMPACT B2) investigators. J
Clin Oncol. 17:1356–1363. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mamounas E, Wieand S, Wolmark N, Bear HD,
Atkins JN, Song K, Jones J and Rockette H: Comparative efficacy of
adjuvant chemotherapy in patients with Dukes' B versus Dukes' C
colon cancer: Results from four National surgical adjuvant breast
and bowel project adjuvant studies (C-01, C-02, C-03, and C-04). J
Clin Oncol. 17:1349–1355. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haller DG, Tabernero J, Maroun J, de Braud
F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll
HJ, et al: Capecitabine plus oxaliplatin compared with fluorouracil
and folinic acid as adjuvant therapy for stage III colon cancer. J
Clin Oncol. 29:1465–1471. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lembersky BC, Wieand HS, Petrelli NJ,
O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall
ME, Jacobs AD, et al: Oral uracil and tegafur plus leucovorin
compared with intravenous fluorouracil and leucovorin in stage II
and III carcinoma of the colon: Results from National surgical
adjuvant breast and bowel project protocol C-06. J Clin Oncol.
24:2059–2064. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2014 for treatment of colorectal cancer. Int J Clin
Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang
RL and Li Q: Cost-effectiveness analysis of colon cancer treatments
from MOSAIC and No. 16968 trials. World J Gastroenterol.
20:17976–17984. 2014.PubMed/NCBI
|
|
10
|
Xie Q, Wen F, Wei YQ, Deng HX and Li Q:
Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon
cancer. Colorectal Dis. 15:958–962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maniadakis N, Fragoulakis V, Pectasides D
and Fountzilas G: XELOX versus FOLFOX6 as an adjuvant treatment in
colorectal cancer: An economic analysis. Curr Med Res Opin.
25:797–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Therapy Evaluation Program (CTEP).
Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40Accessed.
March 6–2017.
|
|
13
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
